A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir

NCT05567952 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

436

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: nirmatrelvir
DRUG: ritonavir
DRUG: placebo for nirmatrelvir

Sponsor

Pfizer